Optimi Health Hails TGA Framework Expansion for Psychedelic Therapies

Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage psychedelic pharmaceutical manufacturer, has welcomed final recommendations from Australia’s Therapeutic Goods Administration (TGA) regarding its Authorized Prescriber scheme for psilocybin and MDMA. The updated framework broadens eligible therapy teams, expands treatment settings beyond hospital environments, and supports scaling of psychedelic-assisted therapy across Australia. This means authorized psychiatrists can now prescribe Optimi’s GMP-compliant MDMA for PTSD and psilocybin for treatment-resistant depression, potentially accelerating adoption of psychedelic-assisted therapy by increasing workforce capacity, particularly in rural and regional areas, while expanding reimbursement opportunities across both public and private payers.

The company highlighted that no serious adverse events have been reported under Australia’s regulated commercial psychedelic treatment program since December 2025, supporting continued expansion of what Optimi describes as the world’s most advanced commercial market for prescribed psilocybin and MDMA therapies. This safety record is crucial for building trust among healthcare providers and patients, and it paves the way for broader acceptance of psychedelic treatments. Optimi Health Corp., a Canadian GMP-certified pharmaceutical manufacturer, specializes in the regulated production and international export of MDMA and psilocybin for prescription-based mental health therapies. With the TGA’s revised framework, Optimi is poised to play a pivotal role in meeting the growing demand for these innovative treatments.

The revised framework could also help overcome barriers to access, such as limited treatment settings and workforce shortages, by allowing therapy to be delivered in more diverse environments. This is particularly significant for rural and regional areas where mental health resources are often scarce. Optimi’s commitment to safety and quality, combined with the TGA’s supportive regulatory changes, positions the company at the forefront of the psychedelic therapy revolution. For more details, visit the full press release at https://nnw.fm/yYW7j. Optimi invites stakeholders to learn more about its mission and products at https://www.optimi.net/.